44 results on '"Farmer, Cristan A."'
Search Results
2. GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study
3. Intravenous delivery of AAV9-GLB1 gene therapy for GM1 gangliosidosis: An interim analysis
4. Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
5. Corrigendum to “Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency”
6. Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion
7. Brain proton MR spectroscopy measurements in CLN3 disease
8. P094: Clinical and MRI correlations in GM1 patients: Finding biomarkers to predict treatment response with gene therapy*
9. Prospective association of psychological pain and hopelessness with suicidal thoughts
10. The relationship between the HDRS insomnia items and polysomnographic (PSG) measures in individuals with treatment-resistant depression
11. Inclusion of individuals with low IQ in drug development for autism spectrum disorder
12. Extracting Latent Subdimensions of Social Communication: A Cross-Measure Factor Analysis
13. Low Incidence of Postdural Puncture Headache Further Reduced With Atraumatic Spinal Needle: A Retrospective Cohort Study
14. Dr. Bishop et al. Reply
15. Mood Induction Paradigm in a Depressed Patient Sample Using Magnetoencephalography
16. Wakefulness After Sleep Onset as Predicting Suicidal Ideation
17. Utilization of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult to Screen Healthy Volunteers for Research Studies
18. The Need for a Developmentally Based Measure of Social Communication Skills
19. F108. The Relationship Between the Habenula, Motivational Symptoms, and Ketamine Treatment
20. S127. Heart Rate Variability in Patients With Treatment-Resistant Depression and Healthy Controls After Treatment With Ketamine
21. S93. Ketamine Treatment Modulates the Kynurenine and Arginine Pathways in Depressed Unipolar and Bipolar Patients
22. Robust clinical outcome measures for patients with juvenile onset GM1 gangliosidosis
23. Disentangling the association of depression on the anti-fatigue effects of ketamine
24. Characterizing the course of suicidal ideation response to ketamine
25. Trajectories of cognitive development in toddlers with language delays
26. F171. Ketamine Modulates Kynurenine Pathway in Mood Disorders: A Longitudinal Structural Equation Model
27. T122. No Hippocampal Volumetric Changes Observed in Patient With MDD Vs. HC Post Ketamine Infusion
28. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
29. RETRACTED: F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen With the Antidepressant Response of Ketamine
30. Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales
31. Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings
32. 3.60 Suicide Risk Prevalence and Clinical Correlates in Youth With Autism Spectrum Disorder
33. 1.10 Social-Emotional and Behavioral Problems in Toddlers With Language Delay
34. Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation
35. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
36. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial
37. State-Dependent Differences in Functional Connectivity in Young Children With Autism Spectrum Disorder
38. Evaluation of Periodic Limb Movements in Sleep and Iron Status in Children With Autism
39. Risperidone Added to Parent Training and Stimulant Medication: Effects on Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, and Peer Aggression
40. What Does Risperidone Add to Parent Training and Stimulant for Severe Aggression in Child Attention-Deficit/Hyperactivity Disorder?
41. Aggressive behavior in a sample of children with autism spectrum disorders
42. Psychometric properties of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP)
43. Development of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP)
44. Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.